Schedule of Investments
ARK Innovation ETF
April 30, 2026 (Unaudited)
| Investments | Shares | Value | ||||||
| COMMON STOCKS–97.3% | ||||||||
| Aerospace & Defense - 3.6% | ||||||||
| Archer Aviation, Inc., Class A* | 17,544,599 | $ | 100,705,998 | |||||
| BWX Technologies, Inc. | 300,508 | 65,026,926 | ||||||
| Kratos Defense & Security Solutions, Inc.* | 1,080,866 | 68,148,602 | ||||||
| Total Aerospace & Defense | 233,881,526 | |||||||
| Automobiles - 9.7% | ||||||||
| Tesla, Inc.* | 1,653,653 | 631,083,594 | ||||||
| Biotechnology - 16.3% | ||||||||
| Beam Therapeutics, Inc.*† | 6,538,304 | 198,306,760 | ||||||
| CRISPR Therapeutics AG (Switzerland)*†(a) | 6,168,251 | 322,846,257 | ||||||
| Intellia Therapeutics, Inc.*†(a) | 9,902,541 | 133,486,253 | ||||||
| Natera, Inc.* | 369,404 | 76,156,328 | ||||||
| Recursion Pharmaceuticals, Inc., Class A*(a) | 21,733,974 | 75,199,550 | ||||||
| Twist Bioscience Corp.*† | 3,382,664 | 197,716,711 | ||||||
| Veracyte, Inc.* | 1,760,142 | 57,943,875 | ||||||
| Total Biotechnology | 1,061,655,734 | |||||||
| Broadline Retail - 3.6% | ||||||||
| Alibaba Group Holding Ltd. (China)(b) | 451,541 | 59,549,227 | ||||||
| Amazon.com, Inc.* | 654,566 | 173,499,264 | ||||||
| Total Broadline Retail | 233,048,491 | |||||||
| Capital Markets - 10.9% | ||||||||
| Bullish (Cayman Islands)*(a) | 3,990,648 | 150,567,149 | ||||||
| Coinbase Global, Inc., Class A* | 1,460,978 | 274,327,839 | ||||||
| Robinhood Markets, Inc., Class A* | 3,825,835 | 278,865,113 | ||||||
| Total Capital Markets | 703,760,101 | |||||||
| Consumer Finance - 0.6% | ||||||||
| SoFi Technologies, Inc.* | 2,176,477 | 35,041,280 | ||||||
| Electrical Equipment - 1.3% | ||||||||
| X-Energy, Inc.*(a) | 2,617,454 | 83,051,815 | ||||||
| Entertainment - 7.5% | ||||||||
| Brera Holdings PLC, Class B (Ireland)*†(a) | 4,219,810 | 3,216,339 | ||||||
| ROBLOX Corp., Class A* | 3,607,025 | 199,324,202 | ||||||
| Roku, Inc.* | 2,407,993 | 280,675,664 | ||||||
| Total Entertainment | 483,216,205 | |||||||
| Financial Services - 1.5% | ||||||||
| Block, Inc.* | 1,411,163 | 99,501,103 | ||||||
| Health Care Equipment & Supplies - 0.3% | ||||||||
| Cerus Corp.* | 9,642,735 | 19,574,752 | ||||||
| Health Care Providers & Services - 0.8% | ||||||||
| GeneDx Holdings Corp.* | 831,221 | 52,275,489 | ||||||
| Interactive Media & Services - 3.1% | ||||||||
| Alphabet, Inc., Class C | 250,688 | 95,747,774 | ||||||
| Baidu, Inc. (China)*(a)(b) | 530,266 | 67,094,557 | ||||||
| Meta Platforms, Inc., Class A | 63,735 | 39,000,084 | ||||||
| Total Interactive Media & Services | 201,842,415 | |||||||
| Investments | Shares | Value | ||||||
| IT Services - 7.2% | ||||||||
| CoreWeave, Inc., Class A* | 1,656,952 | $ | 184,915,843 | |||||
| Shopify, Inc., Class A (Canada)* | 2,340,995 | 283,564,725 | ||||||
| Total IT Services | 468,480,568 | |||||||
| Life Sciences Tools & Services - 9.2% | ||||||||
| 10X Genomics, Inc., Class A*† | 6,786,735 | 149,647,507 | ||||||
| Illumina, Inc.* | 614,284 | 77,854,354 | ||||||
| Pacific Biosciences of California, Inc.* | 14,733,201 | 23,425,790 | ||||||
| Tempus AI, Inc.*(a) | 6,257,544 | 347,168,541 | ||||||
| Total Life Sciences Tools & Services | 598,096,192 | |||||||
| Machinery - 1.2% | ||||||||
| Deere & Co. | 133,860 | 78,959,998 | ||||||
| Semiconductors & Semiconductor Equipment - 11.0% | ||||||||
| Advanced Micro Devices, Inc.* | 947,960 | 336,042,340 | ||||||
| Broadcom, Inc. | 180,911 | 75,517,679 | ||||||
| NVIDIA Corp. | 385,802 | 76,994,505 | ||||||
| Taiwan Semiconductor Manufacturing Co. Ltd. (Taiwan)(b) | 237,249 | 93,964,839 | ||||||
| Teradyne, Inc. | 368,821 | 126,678,949 | ||||||
| Total Semiconductors & Semiconductor Equipment | 709,198,312 | |||||||
| Software - 9.5% | ||||||||
| BitMine Immersion Technologies, Inc.(a) | 6,142,198 | 131,443,037 | ||||||
| Circle Internet Group, Inc.* | 2,740,801 | 249,083,995 | ||||||
| Figma, Inc., Class A*(a) | 1,754,068 | 31,047,004 | ||||||
| Palantir Technologies, Inc., Class A* | 1,459,885 | 203,084,602 | ||||||
| Total Software | 614,658,638 | |||||||
| Total Common Stocks | ||||||||
| (Cost $9,303,519,870) | 6,307,326,213 | |||||||
| PREFERRED STOCK–2.7% | ||||||||
| Software - 2.7% | ||||||||
OpenAI
Group PBC*(c) | 254,476 | 174,999,812 | ||||||
| WARRANTS–0.1% | ||||||||
| Entertainment - 0.1% | ||||||||
| Brera Holdings PLC | 4,316,257 | 2,028,641 | ||||||
| Total Warrants | ||||||||
| (Cost $–) | 2,028,641 | |||||||
| MONEY MARKET FUND–0.0%(d) | ||||||||
| Goldman Sachs Financial Square Treasury Obligations Fund, 3.54%(e) | ||||||||
| (Cost $2,443,616) | 2,443,616 | 2,443,616 | ||||||
| Total Investments–100.1% | ||||||||
| (Cost $9,480,963,298) | 6,486,798,282 | |||||||
| Liabilities in Excess of Other Assets–(0.1)% | (4,331,368) | |||||||
| Net Assets–100.0% | $ | 6,482,466,914 | ||||||
| * | Non-income producing security |
| † | Affiliated security |
| (a) | All or a portion of the security was on loan. The aggregate market value of the securities on loan was $510,558,497; total market value of the collateral held by the fund was $487,389,689.The total market value of the collateral includes non-cash U.S. Treasury securities collateral having a value of $487,389,689. |
| (b) | American Depositary Receipt |
| (c) | Investment fair valued by ARK Investment Management LLC (the “Adviser”) in accordance with the Adviser’s valuation policies and procedures that were reviewed by, and are subject to the oversight of, the Board of Trustees. For fair value measurement disclosure purposes, investment is classified as Level 3. |
| (d) | Less than 0.05% |
| (e) | Rate shown represents annualized 7-day yield as of April 30, 2026. |
Schedule of Investments (continued)
ARK Innovation ETF
April 30, 2026 (Unaudited)
Affiliated Issuer Transactions
An affiliated company is a company in which the Fund has ownership of at least 5% of the voting securities, or a company that is under common ownership or control. Period-to-date transactions with companies which are or were affiliates are as follows:
| Value
($) at 7/31/2025(a) | Purchases Cost ($) | Sales
Proceeds ($) | Net Realized Gain/(Loss) on investments in affiliated securities ($) | Net Change
in Unrealized Appreciation (Depreciation) on investments in affiliated securities ($) | Net Change
in Unrealized Appreciation (Depreciation) on investments in non-affiliated securities ($) | Affiliated Dividend Income ($) | Capital
Gain Distributions ($) | Number
of Shares at 4/30/2026 | Value ($) at 4/30/2026(a) | |||||||||||||||||||||||||||||
| Common Stocks — 15.5% | ||||||||||||||||||||||||||||||||||||||
| Biotechnology — 13.1% | ||||||||||||||||||||||||||||||||||||||
| Beam Therapeutics, Inc. | ||||||||||||||||||||||||||||||||||||||
| 145,737,455 | 575,612,871 | (609,259,717 | ) | 2,113,738 | 84,102,413 | – | – | – | 6,538,304 | 198,306,760 | ||||||||||||||||||||||||||||
| CRISPR Therapeutics AG | ||||||||||||||||||||||||||||||||||||||
| 429,040,448 | 1,158,936,980 | (1,241,282,732 | ) | 22,627,056 | (46,475,495 | ) | – | – | – | 6,168,251 | 322,846,257 | |||||||||||||||||||||||||||
| Intellia Therapeutics, Inc. | ||||||||||||||||||||||||||||||||||||||
| 111,158,927 | 317,685,101 | (316,172,069 | ) | (18,474,841 | ) | 39,289,135 | – | – | – | 9,902,541 | 133,486,253 | |||||||||||||||||||||||||||
| Twist Bioscience Corp. | ||||||||||||||||||||||||||||||||||||||
| 137,016,861 | 440,573,074 | (485,851,104 | ) | (11,650,059 | ) | 117,627,939 | – | – | – | 3,382,664 | 197,716,711 | |||||||||||||||||||||||||||
| Entertainment — 0.1% | ||||||||||||||||||||||||||||||||||||||
| Brera Holdings PLC | ||||||||||||||||||||||||||||||||||||||
| – | 47,940,086 | (20,430,814 | ) | (4,104,586 | ) | (20,188,347 | ) | – | – | – | 4,219,810 | 3,216,339 | ||||||||||||||||||||||||||
| Health Care Equipment & Supplies — 0.0% | ||||||||||||||||||||||||||||||||||||||
| Cerus Corp. ^ | ||||||||||||||||||||||||||||||||||||||
| 14,913,051 | 52,520,000 | (55,034,809 | ) | (673,634 | ) | 51,450,709 | (43,600,565 | ) | – | – | 9,642,735 | 19,574,752 | ||||||||||||||||||||||||||
| Life Sciences Tools & Services — 2.3% | ||||||||||||||||||||||||||||||||||||||
| 10X Genomics, Inc. | ||||||||||||||||||||||||||||||||||||||
| 136,088,916 | 352,715,546 | (406,052,235 | ) | (137,784,561 | ) | 204,679,841 | – | – | – | 6,786,735 | 149,647,507 | |||||||||||||||||||||||||||
| Pacific Biosciences of California, Inc. ^ | ||||||||||||||||||||||||||||||||||||||
| 33,052,192 | 80,028,134 | (88,910,549 | ) | (35,406,542 | ) | 338,991,815 | (304,329,260 | ) | – | – | 14,733,201 | 23,425,790 | ||||||||||||||||||||||||||
| Software — 0.0% | ||||||||||||||||||||||||||||||||||||||
| PagerDuty, Inc. ^ | ||||||||||||||||||||||||||||||||||||||
| 121,452,432 | 210,842,289 | (277,897,780 | ) | (186,598,801 | ) | 132,201,860 | $ | – | – | – | – | – | ||||||||||||||||||||||||||
| $ | 1,128,460,282 | $ | 3,236,854,081 | $ | (3,500,891,809 | ) | $ | (369,952,230 | ) | $ | 901,679,870 | $ | (347,929,825 | ) | $ | – | $ | – | 36,998,305 | $1,005,219,827 | ||||||||||||||||||
| ^ | As of April 30, 2026, the company was no longer considered to be an affiliated security. |
| (a) | The fair value and number of shares of securities are only displayed at the beginning and end of each reporting period when such securities were considered an affiliate as of each date. Refer to the Schedule of Investments for view the fair value and number of shares as of April 30, 2026. |
Schedule of Investments (continued)
ARK Innovation ETF
April 30, 2026 (Unaudited)
Fair Value Measurement
The Fund discloses the fair value of its investments in a hierarchy that distinguishes between: (i) market participant assumptions developed based on market data obtained from sources independent of the Fund (observable inputs) and (ii) the Fund’s own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs). The three levels defined by the hierarchy are as follows:
• Level 1 — Quoted prices in active markets for identical assets.
• Level 2 — Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).
• Level 3 — Significant unobservable inputs (including each Fund’s own assumptions in determining the fair value of investments).
The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.
The following is a summary of the valuations as of April 30, 2026, based upon the three levels defined above:
| ARK Innovation ETF | Level 1 | Level 2 | Level 3 | Total | ||||||||||||
| Assets | ||||||||||||||||
| Common Stocks‡ | $ | 6,307,326,213 | $ | – | $ | – | $ | 6,307,326,213 | ||||||||
| Preferred Stock‡ | – | – | 174,999,812 | 174,999,812 | ||||||||||||
| Warrants | 2,028,641 | – | – | 2,028,641 | ||||||||||||
| Money Market Fund | 2,443,616 | – | – | 2,443,616 | ||||||||||||
| Total | $ | 6,311,798,470 | $ | – | $ | 174,999,812 | $ | 6,486,798,282 | ||||||||
| ‡ | Please refer to the Schedule of Investments to view securities segregated by industry type. |